Published in Eur Urol on June 14, 2006
The metalloproteinase inhibitor Reck is essential for zebrafish DRG development. Development (2012) 1.02
Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. J Gastroenterol (2010) 0.87
Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p. PLoS One (2016) 0.81
Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis. J Transl Med (2013) 0.79
Effect of RECK gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. PLoS One (2012) 0.79
Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas. Neurosurg Rev (2009) 0.77
Differential expression of degradome components in cutaneous squamous cell carcinomas. Mod Pathol (2013) 0.77
RECK Gene Polymorphism is Associated with Susceptibility and Prognosis of Wilms' Tumor in Chinese Children. Med Sci Monit (2015) 0.75
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol (2010) 4.11
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol (2009) 2.60
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol (2010) 2.48
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem (2002) 2.17
MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology (2004) 2.16
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med (Berl) (2005) 2.16
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med (2009) 2.12
Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). BJU Int (2013) 2.10
Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res (2008) 2.06
Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol (2003) 2.04
Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol (2006) 2.00
Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem (2010) 1.99
Comparison of eight computer programs for receiver-operating characteristic analysis. Clin Chem (2003) 1.96
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol (2007) 1.93
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem (2006) 1.88
Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. Arterioscler Thromb Vasc Biol (2007) 1.83
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol (2010) 1.82
Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol (2008) 1.78
Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte. Eur Urol (2006) 1.71
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol (2007) 1.68
Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol (2005) 1.68
Impact of RNA degradation on gene expression profiling. BMC Med Genomics (2010) 1.67
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer (2004) 1.66
ERG rearrangement in small cell prostatic and lung cancer. Histopathology (2010) 1.64
Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol (2006) 1.63
A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005. Eur Urol (2007) 1.62
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. Clin Chem (2011) 1.59
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol (2010) 1.58
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol (2002) 1.56
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (2003) 1.55
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
Influence of tibial slope asymmetry on femoral rotation in patients with lateral patellar instability. Knee Surg Sports Traumatol Arthrosc (2012) 1.50
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res (2005) 1.50
Laparoscopic live donor right nephrectomy: a new technique with preservation of vascular length. J Urol (2002) 1.50
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer (2010) 1.50
Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours. Neuropathol Appl Neurobiol (2015) 1.49
Laparoscopic radical cystectomy with continent urinary diversion (rectosigmoid pouch) performed completely intracorporeally: an intermediate functional and oncologic analysis. Urology (2004) 1.47
Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. Gastroenterology (2006) 1.46
An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. BJU Int (2008) 1.45
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol (2011) 1.44
Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med (2010) 1.43
Laparoscopic dismembered pyeloplasty--the method of choice in the presence of an enlarged renal pelvis and crossing vessels. Eur Urol (2002) 1.43
IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol (2010) 1.43
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. Tumour Biol (2005) 1.41
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate (2004) 1.40
Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res (2006) 1.40
Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol (2012) 1.39
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2011) 1.38
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate (2004) 1.37
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res (2008) 1.37
Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer (2008) 1.34
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol (2010) 1.33
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med (2008) 1.33
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn (2013) 1.30
Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res (2008) 1.29
Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol (2010) 1.28
CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res (2011) 1.28
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer (2008) 1.26
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate (2009) 1.25
Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem (2011) 1.25
Real-time sonoelastography performed in addition to B-mode ultrasound and mammography: improved differentiation of breast lesions? Acad Radiol (2006) 1.23
Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res (2006) 1.23